Market Overview of Vesicare
The overactive bladder market sales have been valued at 2.2 billion in 2020. The market is projected to increase at a CAGR of more than 2 during 2021-2030.
Global Sales and Projections
The overactive bladder market sales were valued at 2.2 billion in 2020. The market is projected to increase at a CAGR of more than 2% during the period 2021-2030. The US accounted for the largest market share in 2020. Key drivers for market growth include the continued uptake of existing therapies and potential launches of new products in the future. Factors such as patent expirations and barriers like low rates of diagnosis and treatment may impact market trends.
FDA Approval and Company Information
The FDA approved Vesicare, manufactured by Astellas Pharma US, Inc., on November 19, 2004, as a treatment for overactive bladder. Camber Pharmaceuticals also launched a generic version of Solifenacin Succinate Tablets in September 2022.
Vesicare FDA Approval History
The FDA approved Vesicare, manufactured by Astellas Pharma US, Inc., on November 19, 2004, as a treatment for overactive bladder. Camber Pharmaceuticals also launched a generic version of Solifenacin Succinate Tablets in September 2022.
Market Expansion and Generic Versions
VESIcare was launched in January 2005. Teva Pharmaceutical introduced a generic version in 2022, offering Solifenacin Succinate Tablets in the US market.
Launch of Generic Vesicare by Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Vesicare (Solifenacin Succinate) Tablets, in 5 mg and 10 mg strengths, in the U.S. market. This introduction expands the treatment options for patients with overactive bladder symptoms.
Drug Price Trends and Sales Data
Drug price trends indicate VESIcare has an average pharmacy cost. Annual sales in the U.S. exceed 955 million, based on IQVIA data from February 2019.
Average Pharmacy Cost for Vesicare
The average pharmacy cost for Vesicare is based on the net of discounts acquired from a US national survey. This data is crucial for understanding the pricing trends and accessibility of Vesicare in pharmacies.
Impact of Market Trends on Vesicare Sales
The market trends have a significant impact on Vesicare sales. Factors such as generic versions entering the market, patent expirations, and evolving consumer behaviors are influencing sales figures. Understanding these trends is crucial for stakeholders to adapt strategies and navigate the changing landscape of the overactive bladder treatment market.